Arch Biopartners (TSXV:ARCH) - Cotización, noticias y análisis

Resumen de acción ARCH

Arch Biopartners Inc., junto con sus filiales, se dedica al desarrollo de fármacos terapéuticos para la inflamación y las lesiones agudas de órganos en Canadá.

Acerca de la empresa

ARCH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Los beneficios han crecido un 4.3% al año en los últimos 5 años

Análisis de riesgos

Tiene menos de 1 año de cash runway

Patrimonio neto negativo

No tiene ingresos significativos (CA$2M)

No tiene una capitalización de mercado significativa (CA$94M)

Competidores de Arch Biopartners Inc.

Sona Nanotech

CNSX:SONA

CA$33.7m

Innovotech

TSXV:IOT

CA$3.9m

Telescope Innovations

CNSX:TELI

CA$17.7m

BioSyent

TSXV:RX

CA$100.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Arch Biopartners
Historical stock prices
Current Share Price	US$1.76
52 Week High	US$2.56
52 Week Low	US$0.97
Beta	1.34
1 Month Change	-26.36%
3 Month Change	25.71%
1 Year Change	-14.56%
3 Year Change	46.67%
5 Year Change	43.09%
Change since IPO	363.16%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ARCH	CA Life Sciences	Mercado CA
7D	-12.9%	0.08%	-0.2%
1Y	-14.6%	1.1%	7.0%

Rentabilidad vs. Industria: ARCH obtuvo unos resultados inferiores a los del sector Canadian Life Sciences , que el año pasado arrojó un rendimiento del 1%.

Rentabilidad vs. Mercado: ARCH obtuvo unos resultados inferiores a los del mercado Canadian, que fue del 5.5% el año pasado.

Volatilidad de los precios

Is ARCH's price volatile compared to industry and market?
ARCH volatility
ARCH Average Weekly Movement	8.3%
Life Sciences Industry Average Movement	6.9%
Market Average Movement	8.9%
10% most volatile stocks in CA Market	18.2%
10% least volatile stocks in CA Market	3.1%

Precio estable de las acciones: El precio de las acciones de ARCH ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ARCH (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	n/a	Richard Muruve	www.archbiopartners.com

Arch Biopartners Inc., junto con sus filiales, se dedica al desarrollo de fármacos terapéuticos para la inflamación y las lesiones agudas de órganos en Canadá. Se centra en el desarrollo de su principal candidato a fármaco, el péptido LSALT, un producto en fase 2 de ensayos clínicos para tratar la inflamación de órganos mediada por la dipeptidasa-1 en pulmones, hígado y riñones. La empresa también desarrolla AB569 para el tratamiento de infecciones bacterianas resistentes a los antibióticos y para el tratamiento de heridas; y Borg, una interfaz péptido-superficie sólida para reducir la corrosión de los metales.

Resumen de fundamentos de Arch Biopartners Inc.

¿Cómo se comparan los beneficios e ingresos de Arch Biopartners con su capitalización de mercado?
Estadísticas fundamentales de ARCH
Capitalización bursátil	CA$110.04m
Beneficios(TTM)	-CA$1.95m
Ingresos (TTM)	CA$1.85m

60.5x

Ratio precio-ventas (PS)

-57.2x

Ratio precio-beneficio (PE)

¿Está ARCH sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ARCH
Ingresos	CA$1.85m
Coste de los ingresos	CA$1.81m
Beneficio bruto	CA$32.20k
Otros gastos	CA$1.98m
Beneficios	-CA$1.95m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.031
Margen bruto	1.74%
Margen de beneficio neto	-105.69%
Ratio deuda/patrimonio	-88.2%

¿Cómo se ha desempeñado ARCH a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ARCH

Recompensas

Análisis de riesgos

Competidores de Arch Biopartners Inc.

CNSX:SONA

CA$33.7m

TSXV:IOT

CA$3.9m

CNSX:TELI

CA$17.7m

TSXV:RX

CA$100.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Recent updates

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.035 loss in 1Q 2023)

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.008 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.003 loss in 1Q 2022)

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Insufficient new directors

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Third quarter 2021 earnings released: EPS CA$0.014 (vs CA$0.037 loss in 3Q 2020)

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

New 90-day low: CA$1.25

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

New 90-day low: CA$1.26

Full year 2020 earnings released: CA$0.077 loss per share (vs CA$0.036 loss in FY 2019)

New 90-day low: CA$1.37

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

New 90-day high: CA$1.56

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

New 90-day low - CA$1.24

Third quarter earnings released

New 90-day low - CA$1.25

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Arch Biopartners Inc.

60.5x

-57.2x

Beneficios e Ingresos